Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo

References

• Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473–491.
   PubMed Web of Science ®Google Scholar
• Le Poole IC, van den Wijngaard RM, Westerhof W, et al. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol. 1997;137:171–178.
   PubMed Web of Science ®Google Scholar
• Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment cell Res. 2003;16:90–100.
   PubMedGoogle Scholar
• Dell’anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment cell Res. 2006;19:406–411.
   PubMedGoogle Scholar
• Schallreuter KU, Chavan B, Rokos H, et al. Decreased phenylalanine uptake and turnover in patients with vitiligo. Mol Genet Metab. 2005;86:27–33.
   Web of Science ®Google Scholar
• Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigment cell Res. 2007;20:271–278.
   PubMedGoogle Scholar
• Stinco G, Piccirillo F, Forcione M, et al. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol. 2009;19:588–593.
   PubMed Web of Science ®Google Scholar
• Nicolaidou E, Antoniou C, Stratigos AJ, et al. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274–278.
   PubMed Web of Science ®Google Scholar
• Lotti TM, Hercogova J, Schwartz RA, et al. Treatments of vitiligo: what’s new at the horizon. Dermatol Ther. 2012;25:S32–S40.
   PubMed Web of Science ®Google Scholar
• Anbar TS, El-Ammawi TS, Barakat M, et al. Skin pigmentation after NB-UVB and three analogues of prostaglandin F(2alpha) in guinea pigs: a comparative study. J Eur Acad Dermatol Venereol. 2010;24:28–31.
   PubMed Web of Science ®Google Scholar
• Anbar TS, El-Ammawi TS, Abdel-Rahman AT, et al. The effect of latanoprost on vitiligo: a preliminary comparative study. Int J Dermatol. 2015; 54:587–593.
   PubMed Web of Science ®Google Scholar
• Bansal S, Sahoo B, Garg V. Psoralen-narrowband UVB phototherapy for the treatment of vitiligo in comparison to narrowband UVB alone. Photodermatol Photoimmunol Photomed. 2013; 29:311–317.
   PubMed Web of Science ®Google Scholar
• Parsad D, Pandhi R, Dogra S, et al. Topical prostaglandin analog (PGE2) in vitiligo–a preliminary study. Int J Dermatol. 2002;41:942–945.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol. 2009;160:861–863.
   PubMed Web of Science ®Google Scholar
• Korobko IV, Lomonosov KM. A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. Dermatol Ther. 2016;6:437–441.
   Google Scholar
• Stanimirovic A, Kovacevic M, Korobko I, et al. Combined therapy for resistant vitiligo lesions : NB-UVB, latanoprost, showed no enhanced efficacy compared to topical latanoprost and NB-UVB. Dermatol Ther. 2016;8:1–5.
   Google Scholar
• Lotti T, Wollina U, Tchernev G, et al. An innovative therapeutic protocol for vitiligo: experience with the use of Fraxel Herbium Laser, topical latanoprost and successive irradiation with UVA - 1 Laser. Open Access Maced J Med Sci. 2018;6:49–51.
   PubMedGoogle Scholar
• Anbar TS, Westerhof W, Abdel-Rahman AT, et al. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photoderm Photoimm Photomed. 2006;22:157–163.
   PubMed Web of Science ®Google Scholar
• Yones SS, Palmer RA, Garibaldinos TM, et al. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol. 2007;143:578–584.
   PubMedGoogle Scholar
• Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol. 2004;29:589–592.
   PubMed Web of Science ®Google Scholar
• Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009;28:86–92.
   PubMed Web of Science ®Google Scholar
• Prota G, Vincensi MR, Napolitano A, et al. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment cell Res. 2000;13:147–150.
   PubMedGoogle Scholar
• Scott G, Leopardi S, Printup S, et al. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J Invest Dermatol. 2004;122:1214–1224.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005;14:323–328.
   PubMed Web of Science ®Google Scholar
• Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42–50.
   PubMed Web of Science ®Google Scholar
• Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol. 2000;191:407–416.
   PubMed Web of Science ®Google Scholar
• Prignano F, Pescitelli L, Becatti M, et al. Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. J Dermatol Sci. 2009;54:157–167.
   PubMed Web of Science ®Google Scholar
• Prignano F, Ricceri F, Bianchi B, et al. Dendritic cells: ultrastructural and immunophenotypical changes upon nb-UVB in vitiligo skin. Arch Dermatol Res. 2011;303:231–238.
   PubMed Web of Science ®Google Scholar
• Ding GZ, Zhao WE, Li X, et al. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin. Arch Dermatol Res. 2015;307:281–289.
   PubMed Web of Science ®Google Scholar
• Fawzy MM, El Maadawi ZM, Hegazy RA, et al. Vitiligo – the story from within: a transmission electron microscopic study before and after narrow-band ultraviolet B. Ultrastruct Pathol. 2016;40:265–275.
   PubMed Web of Science ®Google Scholar
• Gauthier YC, Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment cell Res. 2003;16:322–332.
   PubMedGoogle Scholar
• Benzekri L, Hmamouchi I, Gauthier Y. Possible patterns of epidermal melanocyte disappearance in nonsegmental vitiligo: a clinicopathological study. Br J Dermatol. 2015;172:331–336.
   PubMed Web of Science ®Google Scholar
• Boissy RE, Liu YY, Medrano EE, et al. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol. 1991;97:395–404.
   PubMed Web of Science ®Google Scholar
• Anbar TS, El-Sawy AE, Attia SK, et al. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study. Photodermatol Photoimmunol Photomed. 2012;28:17–25.
   PubMed Web of Science ®Google Scholar